Zacks Investment Research
21 Oct 2026, 15:46 UTC · 2h ago
DHR Q3 Earnings Beat on Biotechnology Strength, Sales in Line
Impact · against what's priced in
Danaher's Q3 results are positive due to a significant margin expansion in the Biotechnology segment and an EPS beat, though organic growth in Diagnostics remains flat. The results highlight a transition where bottom-line growth is being driven by operational efficiency rather than aggressive top-line core sales expansion.
- DHR+0.40
No priced-in read yet
- In context
Adjusted EPS beat estimates by 9.9% at $2.11, driven by a 460 basis point expansion in Biotechnology operating margins to 41.8%. This profitability gain offsets sluggish organic growth in Diagnostics, which rose only 0.5%.
Read from the article alone
Top 1 mover · tap to explore
